Such compounds disrupting YAP–TEAD interaction may be useful for the treatment of Hippo pathway–related diseases (cancer progression, drug resistance, anti-angiogenesis therapy, metastasis, diabetes, and age-related macular degeneration). The gene discussed is YAP1; the disease is age-related macular degeneration.